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Erk1/2 activation contributes to mouse ES cell
pluripotency. We found a direct role of Erk1/2 in
modulating chromatin features required for regu-
lated developmental gene expression. Erk2 binds
to specific DNA sequence motifs typically accessed
by Jarid2 and PRC2. Negating Erk1/2 activation
leads to increased nucleosome occupancy and
decreased occupancy of PRC2 and poised RNAPII
at Erk2-PRC2-targeted developmental genes. Sur-
prisingly, Erk2-PRC2-targeted genes are specifically
devoid of TFIIH, known to phosphorylate RNA
polymerase II (RNAPII) at serine-5, giving rise to its
initiated form. Erk2 interacts with and phosphory-
lates RNAPII at its serine 5 residue, which is con-
sistent with the presence of poised RNAPII as a
function of Erk1/2 activation. These findings under-
score a key role for Erk1/2 activation in promoting
the primed status of developmental genes in mouse
ES cells and suggest that the transcription complex
at developmental genes is different than the com-
plexes formed at other genes, offering alternative
pathways of regulation.
INTRODUCTION
Pluripotent embryonic stem cells (ESCs) are widely used in the
study of epigenetic mechanisms due to their unique properties
in self-renewal and their ability to undergo multilineage differen-
tiation in response to appropriate signaling cues (Ng and Surani,
2011; Young, 2011). ESCs generally have a characteristic epige-
netic signature that reflects their broad developmental potential.
One such signature is a ‘‘poised’’ chromatin state present on
developmental genes (Bernstein et al., 2006; Mikkelsen et al.,
2007). This poised state comprises a bivalent chromatin domain
containing a histone modification associated with transcriptional
activation, histone H3 trimethylated at lysine 4 (H3K4me3),
along with another associated with transcriptional repression,
H3K27me3 (for a review, see Voigt et al., 2013). The H3K4me3678 Cell 156, 678–690, February 13, 2014 ª2014 Elsevier Inc.mark is imposed by the SET1A/B and MLL family of Trithorax
complexes, specifically by the MLL2 complex (Hu et al., 2013),
whereas H3K27me3 is catalyzed and propagated by the Poly-
comb repressive complex 2 (PRC2) (Margueron and Reinberg,
2011). Canonical PRC2 comprises four core polypeptides,
Ezh2, Eed, Suz12, and RbAp46/48, with Ezh2 being the enzy-
matic subunit that catalyzes H3K27me2/3. This Ezh2 activity is
regulated by its partner proteins, such as Jarid2 and Aebp2
(Margueron and Reinberg, 2011). PRC2 occupies a large cohort
of developmental genes in undifferentiated ESCs (Bernstein
et al., 2006; Boyer et al., 2006; Lee et al., 2006). Yet, despite
this prevalent deposition, the determinants responsible for
directing PRC2 occupancy at specific loci are still a focus of
active investigation.
In addition to bivalent chromatin marks, developmental genes
also harbor a particular form of RNAPII that is preferentially
phosphorylated on Ser-5 residues (RNAPIIS5P) (Brookes et al.,
2012; Stock et al., 2007). In ESCs, this form of RNAPII is often
referred to as the poised RNAPII (Brookes and Pombo, 2012),
although the exact transcriptional state has yet to be fully
defined. These chromatin and transcriptional features are re-
garded as representing a transcriptionally poised state that is
amenable to rapid gene induction. Although the enzymes that
catalyze the chromatin modifications comprising this transcrip-
tionally poised state are well understood, less is known about
the upstream ‘‘signal(s)’’ that confers this transcriptional compe-
tency and how specific chromatin signatures are established
and reconfigured during cell fate transitions (Voigt et al., 2013).
Cell fate determination entails signaling pathways that often
activate downstream transcription factors, directing their depo-
sition to specific genomic loci to elicit changes in gene expres-
sion through local changes in chromatin architecture (Badeaux
and Shi, 2013; Johnson and Dent, 2013). However, emerging
evidence suggests that terminal signaling effectors themselves
may also cooperate with chromatin regulators to induce changes
in chromatin organization, highlighting a direct convergence of
signaling effectors on chromatin (Dawson et al., 2009; Go¨ke
et al., 2013; Ho et al., 2011; Klein et al., 2013). Several signaling
pathways that are crucial for ESC pluripotency have been iden-
tified. Among these, the cytokine leukemia inhibitory factor (LIF)
and its downstream signaling effector, Stat3, have been shown
to be critical for self-renewal (Niwa et al., 1998). Conversely,
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Figure 1. Loss of PRC2 Components Abrogates Erk1/2 Activation
(A) Western blot comparing phospho-Erk1/2 (pErk1/2) and phospho-MEK1/2
(pMEK1/2) levels in Eed null ESCs and in Jarid2 stable knockdown (KD) ESCs.
(B)Western blot comparing pErk1/2 and pMEK1/2 as a function of time of Ezh2
knockdown.Fgf4-induced activation of Erk1/2 triggers the transition from
self-renewal to lineage commitment (Kunath et al., 2007). It is
interesting to note that, although LIF primarily activates the
Stat3 signaling pathway, it also induces the Erk1/2 signaling
pathway in conjunction with Fgf4 (Niwa et al., 2009). Erk1/2
signaling is also implicated in modulating the transition between
the pluripotency states of mouse ESCs and epiblast stem cells
(EpiSCs) (Greber et al., 2010). Interestingly, although Erk1/2
signaling drives lineage commitment in mouse ESCs, it is requi-
site for the maintenance of self-renewal in human ESCs (Greber
et al., 2011). A role of Erk2 in transcriptional regulation was also
recently reported for human ESCs (Go¨ke et al., 2013). These
observations underscore the importance of Erk1/2 signaling in
stem cells. Conceivably, the transition between different states
of pluripotency and differentiation necessitates changes in the
chromatin landscape to consolidate gene expression changes.
However, little is known as to how Erk1/2 orchestrates this tran-
sition or the identity of the downstream effectors.
Although the role of Erk1/2 signaling in lineage priming is a
recognized feature of proper ESC differentiation, the functional
significance of PRC2 in ESCs is unclear, stemming from an
incongruity between its prevalent deposition on developmental
genes and the relatively mild defect in self-renewal exhibited
by PRC2 mutant ESCs (Chamberlain et al., 2008; Leeb et al.,
2010; Pasini et al., 2007; Shen et al., 2008). Instead, PRC2
mutant ESCs exhibit impaired differentiation potential in vitro,
which is more consistent with the postimplantation defects
observed in vivo (Faust et al., 1995; O’Carroll et al., 2001; Pasini
et al., 2004). These genetic studies suggest that PRC2 may play
a more important role during lineage commitment. Given the
importance of Erk1/2 signaling in lineage priming, we set out to
determine whether a functional relationship between Erk1/2
activation and PRC2 might exist to bring about proper ESC
differentiation. In the studies presented herein, we analyzed
the downstream effects of Erk1/2 signaling, showing that Erk2
directly impinges on chromatin and serves to regulate both the
deposition of PRC2, as well as the establishment of the poised
RNAPII, specifically on developmental genes.RESULTS
Loss of PRC2 Components Leads to Impaired Erk1/2
Activation
To address a possible functional relationship between Erk1/2
activation and PRC2-mediated repression, we first assessed
the status of Erk1/2 activation in PRC2 mutant ESCs. Inter-
estingly, knockdown of the PRC2 partner protein Jarid2 in
ESCs led to a prominent reduction in phosphorylated Erk1/2
(pErk1/2) without an effect on Erk1/2 protein levels (Figure 1A).
Moreover, an ESC line deficient in the core PRC2 subunit Eed
(Eed/) also exhibited a similar reduction in pErk1/2 levels
(Figure 1A). Assessment of the immediate upstream kinases,
MEK1/2 in their activated phosphorylated forms (pMEK1/2),
confirmed an impaired activation of the Fgf-MEK1/2-Erk1/2
pathway (Figure 1A). Notably, acute depletion of the PRC2 cata-
lytic subunit Ezh2 by inducible small hairpin RNA (shRNA) knock-
down provoked an even stronger reduction in pMEK1/2 and
pErk1/2 (Figure 1B). Collectively, these data suggest that
PRC2 mutant ESCs are defective at the level of MEK1/2-Erk1/
2 activation that may relate to their aberrant differentiation.
Reconfiguration of PRC2 Occupancy on Developmental
Genes upon Erk1/2 Inactivation
To investigate whether Erk1/2 activation and Polycomb-medi-
ated repression are interdependent, we next examined the
effects on PRC2 when Erk1/2 activation is thwarted through
the use of a highly specific MEK1/2 inhibitor, PD0325901 (Ying
et al., 2008). Strikingly, H3K27me3 was reduced on numerous
developmentally regulated genes (Figure S1A available online).
Importantly, self-renewal was preserved in these MEK1/2-
inhibited ESCs, as evidenced by the upregulation of stem cell
markers such as Nanog, Tbx3, and Prdm14 and sustained
repression of lineage-specific genes (Figures S1B and S1C).
Hence, the observed reduction in H3K27me3 does not account
for transcriptional derepression. This finding implicates Erk1/2
signaling in potentiating H3K27me3 deposition onto develop-
mental genes and, together with the data above, suggests an
intricate relationship between Erk1/2 and Polycomb repression.
We next established ESCs that are deficient in both Erk1 and
Erk2 to directly assess the role of these kinases in the context of
Polycomb repression. We first obtained Erk2/ ESCs (Kunath
et al., 2007; Saba-El-Leil et al., 2003) and observed a compensa-
tory upregulation of phospho-Erk1 (Figure 2A), as reported pre-
viously (Kunath et al., 2007; Yao et al., 2003). We next depleted
Erk1 using lentiviral-based shRNA against Erk1 in the Erk2/
ESCs, giving rise to Erk1/2 mutant ESCs (Figure 2A). As in the
case of the MEK1/2-inhibited ESCs, we observed a similar upre-
gulation of pluripotency genes in the Erk1/2 mutant ESCs,
whereas many of the developmental genes remained repressed
(Figure S2). Chromatin immunoprecipitation sequencing (ChIP-
seq) revealed that both H3K27me3 and Jarid2 exhibited a reduc-
tion that was focused primarily around the transcription start
sites (TSS) of developmental genes in the Erk1/2 mutant cells
(Figure 2B), which is essentially consistent with the results
obtained using the MEK1/2 chemical inhibitor (Figure S3A).
This effect appears to be specific for the Polycomb repressive
machinery given that the pattern of H3K4me3 and H3K9me3Cell 156, 678–690, February 13, 2014 ª2014 Elsevier Inc. 679
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Figure 2. Erk1/2 Regulates PRC2 Occupancy on Developmental Genes in ESCs
(A)Western blot for Erk1/2 and pErk1/2 in ESC lines developed toward the generation ofErk1/2mutant ESCs. 1–6 denote different shRNA constructs against Erk1.
(B) Heatmap representations of normalized read density of H3K27me3, H3K4me3, Jarid2, and total RNAPII corresponding to 29,000 annotated TSS (UCSC
database) in WT and Erk1/2 mutant ESCs. The normalized read coverage against library size was calculated in the distance of ±10 kb to TSS with 200 bp bin.
Heatmaps were ranked according to H3K27me3 enrichment in WT ESCs. Color scale represents normalized read density.
(legend continued on next page)
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deposition remained largely unchanged on the developmental
genes (Figures 2B, S3A, and S3B). Examples of genes exhibiting
this specific decrease in H3K27me3 and Jarid2 include theHoxA
gene cluster, a classic target of PRC2 (Figure 2C). However,
further cluster analysis revealed notable exceptions, with
H3K27me3 levels being elevated at other loci (n = 2221) that
mainly encode cytokine signaling molecules (Figures S3C and
S3D and Table S1). A significant reconfiguration of H3K27me3
and a decreased presence of PRC2 at developmental loci
were demonstrated recently in mouse ESCs under ‘‘2i’’ condi-
tions that inhibit both MEK1/2 and GSK3 kinases (Marks et al.,
2012). In our analysis using either the MEK1/2 inhibitor alone or
Erk1/2 mutant cells, the specific loss of Erk1/2 activation re-
sulted in this significant reconfiguration of H3K27me3 deposi-
tion. That some loci contained elevated H3K27me3 levels argues
against a general loss in PRC2 enzymatic activity in accounting
for the diminished H3K27me3 levels at the TSS. Moreover, the
Erk1/2mutant cells did not exhibit any loss in PRC2 components
(Figure S3A), which is in accordance with the findings under 2i
conditions (Marks et al., 2012). Notably, the reduction in
H3K27me3 is not due to increased presence of H3K27me3
demethylases, Jmjd3 and Utx (Figure S3E). Taken together,
our findings suggest that PRC2 targeting and/or its maintenance
at target developmental genes has been compromised upon the
specific loss of Erk1/2 in ESCs.
We next assessed whether H3K27me3 could be restored
upon stable expression of HA-tagged Erk2 in the Erk1/2 mutant
ESCs (‘‘Erk2 rescue’’ ESCs, Figure 2D). ChIP-seq analysis
demonstrated that the genome-wide averaged signal of
H3K27me3 was largely restored in the Erk2-rescue ESCs at
levels comparable to that in wild-type (WT) ESCs (Figures 2E
and S3F). Consistent with the restoration of H3K27me3, both
Ezh2 and Jarid2 occupancies were similarly reconstituted in
the Erk2-rescue cells (Figure 2F). Thus, activation of Erk1/2
signaling appears to impact PRC2 deposition on developmental
promoters, either directly or indirectly. This interdependency be-
tween Erk1/2 signaling and PRC2 functioning suggests an unex-
pected feedback mechanism between these two processes.
Erk2 Is Recruited to a Cohort of Polycomb Target Genes
and Alters Nucleosome Occupancy
To understand how Erk2 impacts PRC2 occupancy on devel-
opmental genes, we tested for the presence of Erk2 at the
promoters of PRC2 target genes. ChIP-seq experiments demon-
strate that Erk2 does indeed bind to developmental genes, as
exemplified by the cases of the HoxA, HoxB gene clusters and
Nkx2-2 (Figure 3A). We verified this Erk2 occupancy by
comparing Erk2 ChIP-quantitative PCR (qPCR) results between
WT versus Erk1/2 mutant ESCs (Figures S4A and S4B). Further-(C) Representative ChIP-seq tracks for H3K27me3, H3K4me3, Jarid2, and RNA
responds to genomic location, and the y axis corresponds to normalized ChIP-s
(D) Generation of Erk2 rescue ESCs in the Erk1/2mutant ESCs. Exogenous Erk2 is
the expression of Erk2 (top) and HA-Erk2 (middle) in the respective cell lines.
(E) Average H3K27me3 profile for WT, Erk1/2 mutant, and Erk2-rescue ESCs,
calculated and normalized by total mapped reads. Histogram window size is ±3
(F) ChIP-qPCR for Ezh2 and Jarid2 inWT, Erk1/2mutant, and Erk2-rescue ESCs. R
two replicates.
See also Figures S1 and S2 and Table S1.more, inactivation of Erk1/2 using the MEK1/2 inhibitor
(PD0325901 alone or 2i) also led to an overall reduction in Erk2
occupancy (Figure 3B). We obtained 2,300 high-confidence
Erk2 enriched regions, of which 45% fall within 3 kb of the TSS
(Table S2). Of these, 90% overlap with H3K27me3 and Jarid2,
corresponding to 700 genes that contained Erk2-Jarid2-
H3K27me3 within 3 kb of the TSS (Figures 3C and 3D and Table
S3). Notably, the majority of the Erk2-enriched regions were
depleted of H3K27me3 and deficient in Jarid2 levels in the
Erk1/2mutant cells (Figures 3C and S3C). Functional annotation
of the Erk2 targets using GREAT (McLean et al., 2010) also
showed strong association with lineage and cell commitment
genes, which is typical of PRC2 regulation (Figure 3E). Examina-
tion of all Erk2-bound genomic sites revealed an overrepresenta-
tion of guanine and adenine (GA)- and guanine and cytosine
(GC)-rich DNA sequence motifs (Figure 3F), which is consistent
with the motifs previously reported for Jarid2 (Li et al., 2010;
Peng et al., 2009). Further support for a direct binding of Erk2
to these repressive genomic regions was obtained using an
in vitro gel shift assay with a representative double-stranded
DNA oligomer containing an endogenously derived motif
sequence (GA rich) from the Pou3f2 locus, along with recombi-
nant Erk2, either WT or mutant in its DNA-binding (DBM) or
kinase (KDM) domain (Hu et al., 2009). As shown in Figure 3G,
WT Erk2 was able to bind to the biotinylated DNA probe,
whereas the DNA binding mutant was ineffectual. Erk2 binding
was independent of its kinase activity (Figure 3G, left, lane 4)
andwas largely unaffected by the presence of competingmutant
oligomer harboring GA/ GT mismatches (Figure 3G, lane 7).
Moreover, competition experiments using probes, either WT
GA rich, mutant GT rich, or GC rich, confirmed an affinity of
Erk2 to GA motif sequences (Figure 3G, bottom right). Taken
together, our data provide compelling evidence that Erk2
binds to specific repressive genomic loci in vivo, likely in a
sequence-specific manner.
We considered the possibility that Erk2 binding to GA-rich
regions might demarcate localized regions of chromatin acces-
sibility. Thus, we performed histone H3 ChIP to directly assess
nucleosome occupancy on select Erk2 binding sites in the
case of (1) WT, (2) Erk1/2 mutant, (3) two independently derived
Erk2-rescue cell lines, and (4) ESCs treated with either MEK1/2
inhibitor alone or (5) with both MEK1/2 and GSK3 inhibitors (2i).
The results show a modest but consistent increase in H3 occu-
pancy on the Erk2-enriched regions tested in all the ESC lines
wherein Erk1/2 was inactivated, relative to the cases of Erk2-
rescue and WT ESCs (Figure 4). On the other hand, H3 occu-
pancy on pluripotency genes, represented by Oct4 and Sox2
promoters, was essentially similar, irrespective of Erk1/2 status
(Figure 4). The addition of GSK3 inhibitor alone did not lead toPII on the HoxA gene cluster in WT and Erk1/2 mutant ESCs. The x axis cor-
eq signal density.
fused to an HA epitope tag and a downstream IRES-GFP. Western blots show
centered on TSS. The average read coverage of 29,000 TSS regions was
kb with 10 bp bin size.
esults are presented as a percentage of input material. Bar representsmean of
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Figure 3. Erk2 Binds to Polycomb-Regulated Developmental Genes
(A) ChIP-seq gene tracks showing occupancy of Erk2 on PRC2 target genes. The x axis corresponds to genomic location, and the y axis corresponds to
normalized ChIP-seq signal density.
(B) Average Erk2 profile for WT and MEK1/2 inhibited (PD0325901 and 2i) ESCs, centered on TSS. The average read coverage of 29,000 TSS regions was
calculated and normalized by total mapped reads. Histogram window size is ±10 kb with 10 bp bin size.
(C) Heatmaps of H3K27me3 and Jarid2 normalized read distribution on all 2,296 Erk2-enriched regions. H3K27me3 and Jarid2 are present in themajority of Erk2-
enriched regions in WT ESCs but are depleted in Erk1/2mutant cells. Data matrix was constructed with Erk2 peak regions centered by peak summit with ±5 kb
extension on both sides and a bin size of 50 bp, as described in the Extended Experimental Procedures.
(D) Venn diagram of the overlap among target genes of Erk2, Jarid2, and H3K27me3 in WT ESCs. In this case, only respective target genes with at least one peak
within 3 kb of the TSS were considered. A smaller list comprising Jarid2 and H3K27me3 target genes was generated by first annotating Jarid2 and H3K27me3
peaks to Erk2, as described in the Extended Experimental Procedures.
(E) GO term analysis of all Erk2 targets.
(legend continued on next page)
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Figure 4. Erk1/2 Regulates Nucleosome
Occupancy
Comparison of histone H3-ChIP qPCR for select
Erk2-PRC2-bound developmental genes among
WT ESCs, two independent Erk2-rescue lines
(rescue 1 and rescue 2), and WT ESCs treated with
MEK1/2 inhibitor (PD03) or with both MEK1/2 and
GSK3 inhibitors (2i).Oct4 and Sox2 represent active
genes, and the remaining represent Erk2-PRC2
developmental genes. Results are presented as a
percentage of input material. Bar represents SD of
two replicates. The asterisk (*) denotes p < 0.05, the
pound sign (#) denotes p < 0.2, and n.s. denotes not
significant. A two-tailed Student’s t test was per-
formed.
See also Figure S5.any alterations in H3 occupancy on the Erk2 regions tested
(Figure S5). These results suggest that Erk1/2 activation may
be required for appropriate modulation of nucleosome occu-
pancy in ESCs given that Erk2 binding corresponds to regions
of histone eviction, and its loss promotes increased nucleosome
density.
Activated Erk1/2 Regulates Establishment of Poised
RNAPII on Polycomb Target Genes
Interestingly, despite the apparent reduction in PRC2 occupancy
when Erk1/2 signaling is impaired, many of these Erk2-targeted
developmental genes remained repressed (Figures S2 and S6A).
Recent studies detected the presence of a poised form of
RNAPII(S5P) on PRC2 target promoters that likely contributes
to the facultative transcriptional state of these developmental
genes in undifferentiated ESCs (Brookes et al., 2012; Stock
et al., 2007). Thus, we next compared the status of RNAPII
(S5P) in WT versus Erk1/2 mutant cells by ChIP-seq. Erk1/2
mutant cells exhibited a significant reduction in RNAPII(S5P)
occupancy on Erk2-PRC2 bound promoters such as the HoxA
gene cluster and Cebpa, but not on active genes such as Nanog
(Figure 5A). Importantly, genome-wide analysis confirmed that
this reduction in RNAPII(S5P) was specific for Erk2-PRC2-bound
promoters and was not relevant in the case of highly active
promoters (Figure 5B). Consistently, there were no detectable
changes in RNAPII(S5P) levels in the case of the control group
of silenced genes, as expected (Figure 5B). Moreover, the reduc-
tion in RNAPII(S5P) observed for Erk2-PRC2 genes cannot be
attributed to a general reduction in RNAPII occupancy (Figures
5A and S6A). We also extended this analysis to include ESCs
treated with MEK1/2 inhibitor and observed a similar depletion
of RNAPII(S5P) on select developmental genes (Figure S6B).
Thus, abrogation of Erk1/2 leads to a specific reduction in(F) Motif analysis of all Erk2-enriched regions using MEME. Two distinct motifs w
(G) Left, gel shift assay comparing recombinant Erk2, either WT or mutant in DBM
from the Pou3f2 locus. Top right, gel shift titrations and binding curve of WT- an
presence of the Pou3f2 GA-rich DNA probe. Bottom right, graph showing the ef
binding between WT Erk2 and the GA-rich DNA probe. ‘‘wt’’ denotes WT probe,
See also Figures S3 and S4 and Tables S2 and S3.RNAPII(S5P) on PRC2 target genes. That the absence of the
well-recognized kinase Erk1/2, or impairment of its activity, leads
to loss of the poised version of RNAPII at developmental loci, led
us to investigate whether Erk1/2 itself is responsible for the
phosphorylation of Ser-5 on the C-terminal domain (CTD) of
RNAPII at developmental genes in ESCs. The results of in vitro
kinase assays indicate that Erk2 is able to phosphorylate
RNAPII on Ser-5 (Figure 5C). Moreover, Erk2 interacts with
RNAPII in vivo as evidenced by endogenous immunoprecipita-
tion experiments (Figure 5C, right).
These findings are consistent with Erk2 (and likely Erk1)
contributing to direct phosphorylation of RNAPII on Ser-5, spe-
cifically at targeted developmental genes. However, it is gener-
ally accepted that phosphorylation of Ser-5 (as well as Ser-7)
on the CTD of RNAPII is largely mediated by the TFIIH complex
(Akhtar et al., 2009; Komarnitsky et al., 2000; Lu et al., 1992).
Therefore, we next assessed the presence of TFIIH in WT versus
Erk1/2 mutant ESCs using ChIP-seq for Ercc3, the largest
subunit of the TFIIH complex (Drapkin et al., 1994; Schaeffer
et al., 1993). Strikingly, Ercc3 showed an enrichment pattern
inverse to that of Erk2 in the WT case. Unlike Erk2, Ercc3 was
largely absent on low/inactive promoters and was specifically
enriched on highly active promoters such as Klf2 and histone
gene cluster 1 (Figures 5D, 5E, and S6C). It should be empha-
sized that the decrease in RNAPII(S5P) occupancy in the Erk1/
2 mutant cells was only observed on developmental genes and
not on highly active genes (Figure 5B). Notably, in the Erk1/2
mutant ESCs, the highly active genes showed, on average, an
increased Ercc3 promoter signal (Figure 5E), mirroring the gain
in RNAPII(S5P) (Figures 5B and S6A). This is in accordance
with the well-documented role of TFIIH in promoting transcrip-
tion initiation (Kim et al., 2000; Kumar et al., 1998). Importantly,
inhibition of TFIIH activity by Triptolide (Titov et al., 2011) resultsere identified (GA and GC rich).
or KDM in the presence of a probe containing a biotinylated GA motif derived
d KDM- Erk2. Increasing amounts of Erk2 proteins were used (0–10 mg) in the
fects of increasing amounts of different cold probes (0–2503) in affecting the
whereas ‘‘mt’’ denotes mutant GA/ GT probe.
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Figure 5. Interplay between Erk2 and TFIIH
Determines Transcriptional States
(A) Representative ChIP-seq gene tracks showing
loss of RNAPII(S5P) on developmental genes (HoxA
cluster and Cebpa), but not on the active gene,
Nanog. WT denotes WT ESCs and Mutant denotes
Erk1/2 mutant ESCs. The gene tracks for
H3K27me3, Jarid2, and RNAPII are also shown. The
x axis represents genomic locus, and the y axis
corresponds to normalized read density.
(B) Average normalized profiles of RNAPII(S5P) inWT
and Erk1/2mutant cells for different cohorts of genes
as designated. Reads were centered at either
±500 bp or ±10 kb to the TSS. ‘‘High expressed’’ and
‘‘silent’’ genes represent the top 2,000 most active
and bottom 2,000 least expressed genes in mouse
ESCs, respectively, as described in the Extended
Experimental Procedures. The Erk2-PRC2 group
refers to the cohort of genes bound by Erk2 and
H3K27me3, as classified in Figure 3D. A 10 bp bin
was used in the plot generation.
(C) Left, in vitro kinase assay using Erk2 and
RNAPII-CTD as substrate. Right, endogenous
coimmunoprecipitation using HA antibody and
extracts of WT ESCs (control) or ESCs stably ex-
pressing HA-tagged Erk2.
(D) Top, Ercc3 is only present on active genes
(such as Klf2 and histone gene cluster) in ESCs, but
not on Erk2-PRC2-bound developmental genes
such as Gata6.
(E) Average profile of Ercc3 in WT and Erk1/2mutant
ESCs, based on gene expression levels (similar to
the classification used in Figure 5B). A 10 bp bin was
used in the generation of the plots.
(F) ChIP-qPCR for RNAPII(S5P) comparing Ercc3-
bound and Erk2-bound targets following Triptolide
treatment (1 mM for 30min). Bar represents SD of two
replicates.
(G) ChIP-qPCR for RNAPII(S5P) showing restoration
of RNAPII(S5P) on developmental genes upon WT
Erk2 expression, but not in the case of the KDM. Bar
represents SD of two replicates.
(H) ChIP-qPCR for Ezh2 showing restoration of Ezh2
on developmental genes upon WT Erk2 expression,
but not in the case of KDM. Bar represents SD of two
replicates.
See also Figure S6.in a selective decrease in RNAPII(S5P) signal on Ercc3-target
genes such as Klf2 and Hist1h1a, but not on Erk2-bound devel-
opmental genes (Figures 5F and S6D). This finding thus provides
additional support for a TFIIH-independent role of Erk2 in the
establishment of RNAPII(S5P) on developmental genes. Finally,
to ascertain that phosphorylation of RNAPII at Ser-5 is depen-
dent on the kinase activity of Erk2, we performed rescue exper-
iments to compare the ability of Erk2, either WT or mutant in its684 Cell 156, 678–690, February 13, 2014 ª2014 Elsevier Inc.kinase domain, to restore RNAPII(S5P)
levels on developmental genes. Whereas
expression of WT Erk2 led to a significant
increase in RNAPII(S5P) levels on develop-
mental genes relative to Erk1/2 mutant
cells, expression of Erk2-KDM was ineffec-tual (Figures 5G and S6E). Moreover, specific to the case of the
WT Erk2 rescue cells, the restoration of RNAPII(S5P) was
accompanied by an increase in Ezh2 occupancy on the same
developmental loci (Figure 5H). Taken together, our in vitro, as
well as in vivo, data strongly indicate that activated Erk2 is likely
a bona fide RNAPII CTD kinase in ESCs and, through its kinase
activity, is responsible for the establishment of the poised chro-
matin features on developmental genes.
Dynamics of Erk2 Binding during ESC Differentiation
The results thus far have shown that Erk1/2 directly accesses
PRC2 target genes and impacts RNAPII(S5P), as well as PRC2
occupancy in ESCs. If PRC2 functions downstream of Erk1/2
activation to preclude gene activation in the ESC state, then
transcription activation of development genes during differentia-
tion should be accompanied by the loss of Erk2 binding and
alleviation of PRC2-mediated repression. Indeed, Erk2 binding
on developmental genes was reduced as a function of retinoic
acid (RA)-mediated ESC differentiation, as early as day 2 of
differentiation and concomitant with transcription activation
(Figures 6A and S7). We next followed the dynamics of Erk2
binding and RNAPII occupancy during early events of ESC
conversion to EpiSC, whereby changes in gene expression
occur more gradually. Developmental genes known to be upre-
gulated in EpiSCs, relative to ESCs, e.g., Eomes, Otx2, and
Zic2, exhibited the expected activation, along with decreased
Erk2 binding (Figure 6B). On the other hand, Gbx2, whose
expression is upregulated in ESCs relative to EpiSCs, showed
the reverse trend, with RNAPII decreasing and Erk2 occupancy
increasing as a function of differentiation (Figure 6B). Notably,
an unbiased analysis of all Erk2 target genes supports a general
inverse correlation between Erk2 occupancy and transcriptional
activity during differentiation (Figure 6C).
DISCUSSION
The presence and functional significance of poised RNAPII
(S5P) on developmental genes have been a subject of debate.
Although genome-wide RNAPII ChIP-seq studies have revealed
a widespread presence of low levels of RNAPII at inactive
promoters, including those bound by PRC2 (Guenther et al.,
2007; Kim et al., 2005; Muse et al., 2007; Zeitlinger et al.,
2007), many outstanding questions remain regarding the regula-
tion of RNAPII recruitment to these loci, the identity of the CTD
kinase(s) responsible for its Ser-5 phosphorylation, and the exact
transcriptional configuration of this particular form of RNAPII,
RNAPII(S5P). Recent studies have reassessed the transcrip-
tional status of Polycomb repressed genes and found that
Polycomb binding is surprisingly compatible with moderate
gene expression (Brookes et al., 2012; Enderle et al., 2011;
Kaneko et al., 2013) and, hence, may facilitate the fine-tuning
of gene expression, rather than enforce an obligatory silencing.
This reflects a paradigm shift in how Polycomb proteins are
widely perceived to regulate gene expression in mammals.
Furthermore, the detection of stalled RNAPII on Polycomb
targets (Chopra et al., 2009; Min et al., 2011; Stock et al.,
2007), coupled with the detection of short RNAs emanating
from these loci (Kanhere et al., 2010), implies an interplay
between PRCs and the transcriptional apparatus (Brookes
et al., 2012; Enderle et al., 2011; Min et al., 2011). Indeed, our
results showing interplay between Erk1/2 activity and both
RNAPII and PRC2 bear directly on this intricate regulation.
In this study, we describe the unexpected deposition of Erk2
on developmental promoters, as well as the corresponding
decrease in RNAPII(S5P) upon Erk1/2 inactivation. Notably, the
reduction in RNAPII(S5P) is specific to developmental genes
and not active ones. These observations, along with thosedemonstrating the ability of Erk2 to interact with and phosphor-
ylate RNAPII at the Ser-5 residue (Trigon et al., 1998), as also
shown here, point to Erk2 being a bona fide Ser-5 RNAPII CTD
kinase that acts primarily at developmental loci. This supposition
is in accordance with earlier biochemical studies showing that
Erk1/2 preferentially targets Ser-5, but not other serine residues
on the CTD (Bonnet et al., 1999; Dubois et al., 1994; Trigon et al.,
1998), as well as the implication of mitogen-activated protein
kinases (MAPKs) in RNAPII phosphorylation during early devel-
opment in vivo (Bellier et al., 1997), and during heat shock
(Venetianer et al., 1995). Buttressing this role of Erk1/2 is the
complementary, also unexpected, finding that the presence of
TFIIH at developmental genes is low and/or undetectable and
that the levels of RNAPII(S5P) on these loci are unperturbed
upon TFIIH inhibition by Triptolide, yet sensitive to Erk2 activa-
tion. This specific deficiency in TFIIH is in line with the reported
lack of RNAPII(S7P) (also imposed by TFIIH) on Polycomb target
genes (Brookes et al., 2012). Notably, the lack of TFIIH on the
developmental loci cannot be simply attributed to a lower level
of transcription initiation at these loci relative to active genes
(Figure S6F). Although we cannot completely rule out that a
very low and/or transient occupancy of TFIIH may exist, our
results clearly underscore a previously unrecognized role of
Erk1/2 kinase in catalyzing RNAPII(S5P) at these developmental
promoters. Future studies will address the interplay between
these two CTD kinases and whether certain roles may be sub-
sumed and/or interchanged during transcription initiation.
The CTD of mammalian RNAPII contains 52 repeats of the
heptapeptide, which contains the consensus sequence Tyr-
Ser-Pro-Thr-Ser-Pro-Ser. Despite the similarity in sequence,
previous studies in yeast have demonstrated that not every
heptapeptide repeat in the CTD is functionally equivalent (Nonet
et al., 1987; Scafe et al., 1990). We postulate that Erk-mediated
phosphorylation of the CTD is specific to developmental genes
and that this occurs at unique heptapeptide(s) within the CTD,
perhaps distinct from those targeted by TFIIH (see model in
Figure 7). In light of our previous reports demonstrating that
the Ercc3 subunit of TFIIH is necessary for the establishment
of an open complex (Kim et al., 2000), how then is transcription
initiation achieved on developmental genes in its absence? Pre-
vious studies had demonstrated that the TFIIH requirement for
transcription could be bypassed upon induced superhelicity of
the DNA template (Goodrich and Tjian, 1994; Parvin and Sharp,
1993). Thus, it will be interesting to assess any changes in pro-
moter DNA topology on these developmental genes as a func-
tion of Erk activity and how that relates to transcriptional priming.
Notably, Erk2 target genes are highly enriched for DNA Topo-
isomerase 2a (Top2a, an enzyme required to resolve torsional
stress resulting from DNA supercoiling), despite a conspicuous
lack of Ercc3 occupancy (data not shown). This corroborates
our interpretation that distinct mechanisms may be in place to
regulate transcription initiation on active versus poised genes.
Collectively, based on our findings and those of Parvin and Sharp
(1993), as well as Goodrich and Tjian (1994), we propose that
combinatorial utilization of different Ser-5 RNAPII CTD kinases
and differential phosphorylation of different CTD repeats are
necessary to activate or prime gene expression in ESCs. Pro-
moters bound by Erk2 may be competent for transcription asCell 156, 678–690, February 13, 2014 ª2014 Elsevier Inc. 685
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Figure 6. Dynamics of Erk2 Binding during Differentiation
(A) ChIP-qPCR for Erk2 showing loss of Erk2 binding on Erk2-PRC2 targets upon retinoic acid differentiation (day 0 to day 6). Results are presented as a
percentage of input material. Bar represents SD of two replicates.
(B) Top, ChIP-seq tracks showing the kinetics of Erk2 binding and RNAPII occupancy during mouse ES to EpiSC differentiation (day 1 to day 3). Bottom, mRNA
expression levels of the target genes specified, normalized to Gapdh. Bar represents SD of two replicates.
(legend continued on next page)
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Figure 7. Model
In the presence of basal Erk1/2 activity, lineage-specific promoters exist in a permissive chromatin state. Erk2 can access and bind to underlying sequences,
including specific DNAmotifs that are rich in GA dinucleotides, and/or to promoter CpG islands. (i) At promoters, binding of Erk2 may potentially antagonize TFIIH
recruitment. Through its own kinase activity, Erk2 phosphorylates Ser-5 in a particular RNAPII CTD heptad repeat, thus establishing a stalled/poised form of
RNAPII that permits regulated transcription of promoter-derived ncRNAs or nascent transcripts (represented as black dashed lines). This event may trigger the
subsequent recruitment of PRC1/2 complexes to buffer/fine-tune gene expression. (ii) Upon gene activation, Erk2 is displaced, and TFIIH must be recruited,
alongside other transcription factors (TFs) and cofactors to promote robust gene activation (mRNA is represented by black solid lines). TFIIH may target a CTD
heptad repeat distinct from that of Erk2. (iii) Erk2 also binds to nonpromoter regions and may help potentiate Jarid2/PRC2 targeting and/or spreading through an
initial wave of nucleosome eviction. (iv) In the absence of Erk1/2, developmental promoters may assume a more ‘‘inert’’ chromatin state with increased
nucleosome stability and reduced propensity for permissive transcription. PRC2 may thereby be rendered dispensable on these developmental genes.evident by high levels of RNAPII(S5P) and Top2a, but robust
transcription likely occurs only upon subsequent recruitment of
the multisubunit TFIIH complex, which fosters robust promoter
melting and clearance through its different components (Compe
and Egly, 2012). This is in good agreement with our data showing
a progressive displacement of Erk2 on developmental genes in
anticipation of transcription activation during differentiation.
This proposed interplay between Erk and TFIIH may be analo-
gous to the recent description of TFIIH in transcriptome amplifi-
cation during B cell activation (Kouzine et al., 2013).
As shown here, the loss of Erk1/2 signaling also results in
alterations in chromatin accessibility and a profound impact
on PRC2 deposition. Negligible changes were observed for
H3K4me3 and H3K9me3 depositions on developmental genes.(C) Scatterplot of Erk2 and RNAPII occupancy at Erk2 target genes during ES to Ep
of normalized ChIP-seq read density for Erk2 and RNAPII (total) mapping within ±
target genes, and gray dots represent all other TSS. Correlation coefficient is .
See also Figure S7.This is in line with the dynamic and plastic nature of the
Polycomb repressive machinery, the recruitment of which is
attuned to environmental perturbations (Prezioso and Orlando,
2011). We speculate that Erk1/2-induced changes in chromatin
accessibility may be key to potentiating PRC2 recruitment.
Mechanistically, the increased nucleosome occupancy at
Erk2-bound regions in the absence of Erk1/2 activation may
occlude underlying DNA elements involved in PRC2 recruitment,
thereby precluding focal deposition of H3K27me3. Interestingly,
motif analysis of all Erk2 binding sites revealed a conspicuous
enrichment for GA dinucleotides. This GA-rich polypurine motif
was also previously described for Jarid2 (Peng et al., 2009), as
well as the noncoding RNA (ncRNA), HOTAIR (Chu et al.,
2011). It is noteworthy that a substantial proportion of Erk2iSC conversion (day 1 to day 3). x and y axes indicate the log2 ratio (day1/day3)
3 kb of each TSS. Black dots correspond to the TSS of high-confidence Erk2
34
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also resides in intergenic and intronic regions, apart from pro-
moters. These observations raise a tantalizing possibility that
Erk2 binding sites may demarcate genomic regions for Poly-
comb nucleation and subsequent spreading, perhaps analogous
to that of Drosophila Polycomb response element (PRE). Our
observation that Erk1/2 activation can regulate nucleosome
disruption is of particular relevance given that PREs are typically
depleted of nucleosomes (Mohd-Sarip et al., 2006). As such, it is
conceivable that Erk1/2 may be part of a larger protein ensemble
that is targeted to these putative Polycomb binding sites, and
through local nucleosome turnover, promotes subsequent
PRC2 recruitment (see model in Figure 7). Further investigation
is needed, on a genome-wide level, to precisely define how
changes in global nucleosome occupancy impact PRC2 recruit-
ment and its relationship to RNAPII stalling (Gilchrist et al., 2010).
In addition to the aforementioned GA motif, other DNA
elements, including transcription factor binding sites and pro-
moter unmethylated CpG islands, have been implicated in
PRC2 recruitment (for a review see Simon and Kingston, 2013).
At least in ESCs, the latter have been shown to play a causal
role in PRC2 recruitment (Lynch et al., 2012; Mendenhall et al.,
2010), and notably, in silico analysis reveals that increasing
density of promoter CpG islands apparently correlates with the
extent of H3K27me3 deposition (Orlando et al., 2012). Thus, an
additional interesting hypothesis is that multiple CpG islands
may potentiate the generation of nascent primary transcripts
and/or ncRNAs that serve to recruit and/or facilitate PRC2 bind-
ing (see model in Figure 7). Indeed, a previous study determined
that short ncRNAs are transcribed from PRC2 target loci
(Kanhere et al., 2010). Although it remains to be formally tested
whether these CpG-related ncRNAs indeed direct PRC2 deposi-
tion, it nevertheless highlights a potential link between promoter
effect transcription and PRC2 recruitment in cis. In this regard,
our in vivo rescue experiments (Figures 5G and 5H) showing
the concomitant restoration of both RNAPII(S5P) and PRC2
upon Erk activation are largely supportive of this hypothesis
and point toward a modus operandi wherein PRC2 recruitment
occurs in a hierarchical manner downstream of transcriptional
activity (see also Kaneko et al., 2013).
It was previously reported that Jarid2-deficient ESCs fail to
efficiently establish the poised RNAPII on PRC2 targets (Land-
eira et al., 2010). That Jarid2/PRC2-deficient cells are compro-
mised in Erk1/2 activation as shown here may account, at least
in part, for the reduced levels of RNAPII(S5P) on developmental
genes. However, it remains unclear how loss of Jarid2/PRC2
impacts Erk1/2 activation. This may occur indirectly through
the upregulation of Prdm14, a known target of PRC2, impli-
cated in the attenuation of the Fgf-Erk pathway (Grabole
et al., 2013; Yamaji et al., 2013), and/or through misregulation
of other signaling cascades, such as the LIF/Stat3 pathway,
that also contribute toward Erk1/2 activation in ESCs (Niwa
et al., 2009).
In summary, our data demonstrate how Erk1/2-induced
effects on RNAPII poising and chromatin architecture may
potentiate changes in PRC2 occupancy in ESCs and emphasize
the importance of signal-induced chromatin remodeling as a key
epigenetic priming event that underlies the transcriptional
competent state of developmental promoters in ESCs.688 Cell 156, 678–690, February 13, 2014 ª2014 Elsevier Inc.EXPERIMENTAL PROCEDURES
Mouse ESC Maintenance and Differentiation
All ESCs were grown in standard ESCmedium containing LIF unless otherwise
stated. Erk2/ ESCs were a kind gift from Dr. Sylvain Meloche. Erk1/2mutant
ESCs were maintained in the presence of 1 mg/ml puromycin, and Erk2-rescue
ESCs were maintained in 150 mg/ml hygromycin and 1 mg/ml puromycin. For
2i ESCs, 1 mM MEK1/2 inhibitor (PD0325901) and 3 mM GSK3 inhibitor
(CHIR99021) were used. See also Extended Experimental Procedures.
Cloning, Transfections, and shRNA Knockdown
pLKO-based Erk1 lentiviral shRNA (TRCN0000023184) or control GFP shRNA
(Thermo Scientific) plasmids were used to produce the lentiviruses. For gener-
ation of Erk2-rescue ESCs, Erk2 cDNA was PCR amplified from ESCs and
cloned into pCAGIG (GFP-marker) or pCAGIH (Hygromycin-marker) expres-
sion vectors. Site-directed mutagenesis was carried out to obtain the KDM
construct. See Extended Experimental Procedures for details on primer
sequences.
EMSA
Each binding reaction was carried out with 1 ng of biotinylated dsDNA probe
and 1 mg of Erk2 recombinant protein in 25 ml reaction buffer (50 mM HEPES
[pH 7.9], 250 mM KCl, 2.5 mM EDTA, 25% glycerol, 5 mg BSA, and 10 ng dI/
dC). Reactions were carried out for 1 hr at room temperature, separated on
a 6% native TGE polyacrylamide gel at 4C, and visualized using the LightShift
EMSA kit (Pierce/Thermo).
Triptolide Treatment
Triptolide was obtained from InvivoGen (catalog ant-tpl). ESCs were treated at
the stated concentrations for 30 min.
ChIP-PCR and ChIP-Seq
ChIP assays were performed as described previously (Gao et al., 2012).
ChIP westerns were also performed for each antibody used. For ChIP-seq,
up to 30 ng of immunoprecipitated DNA was end repaired, A tailed, and
ligated to custom barcode adapters with T4 ligase. Libraries were sequenced
on Illumina HiSeq. A custom barcoding system was employed. The SRA
accession number is SPR028688. See the Extended Experimental Proce-
dures for details on antibodies, Q-PCR primer sequences, and computational
analysis.ACCESSION NUMBERS
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